REG - Silence Therapeutics - Silence to Participate in US Investor Conferences

Silence TherapeuticsAnnouncement

03/09/2020 07:01

RNS Number : 8635X
  
Silence Therapeutics PLC
  
03 September 2020
  
 

Silence Therapeutics to Participate in Virtual U.S. Investor Conferences in September
 
3 September 2020
 
LONDON, Silence Therapeutics plc (LON: SLN) ("Silence" or "the Company"), a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, today announces that Company management will present a Company overview and host one-on-one meetings during four upcoming virtual investor conferences, details of which can be found below:
 
Wall Street Investor Forum Virtual Conference
 



Date:






Thursday, September 10, 2020




Time:






12:00 pm EDT (17:00 BST)



 
H.C. Wainwright 22nd Annual Global Investment Conference

















Date:






Tuesday, September 15, 2020




Time:






11:30 am EDT (16:30 BST)



 
Morgan Stanley 18th Annual Global Healthcare Conference

















Date:






Thursday, September 17, 2020




Time:






12:30 pm EDT (17:30 BST)



 
Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

















Date:






Tuesday, September 22, 2020




Time:






10:00 am EDT (15:00 BST)



 
Live webcasts of the Company's presentations can be accessed via the Investors section of the Company's website at www.silence-therapeutics.com. An archived replay of the webcasts will be available for 60 days on the Company's website after the conference.
 
 
 
 
For more information, please contact:
 



Silence Therapeutics plc
Iain Ross, Executive Chairman
Rob Quinn, Chief Financial Officer
 
 


Tel:  +44 (0)20 3457 6900




Investec (Nominated Adviser and Broker)
Daniel Adams/Gary Clarence
 
 


Tel:  +44 (0) 20 7597 5970




European IR
Consilium Strategic Communications
Mary-Jane Elliott/Chris Welsh/Angela Gray
silencetherapeutics@consilium-comms.com 
 


Tel: +44 (0) 20 3709 5700




U.S. IR
Westwicke
Peter Vozzo
peter.vozzo@westwicke.com


 Tel: +1 (443) 213-0505



 
 
About Silence Therapeutics plc
Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, within its cells. Its proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-associated proteins. Silence's proprietary RNA chemistries and delivery systems are designed to improve the stability of molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases. The Company has secured high value research and collaboration agreements with AstraZeneca, Mallinckrodt Pharmaceuticals and Takeda. For more information, please visit: https://www.silence-therapeutics.com/
 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
MSCEASNAEFPEEFA